TG Therapeutics, Inc. (TGTX) |
|
17.5655 -0.405 (-2.25%)
|
02-03 14:48 |
|
Open: |
17.47 |
Pre. Close: |
17.97 |
|
High:
|
18.31 |
Low:
|
17.2 |
|
Volume:
|
2,734,470 |
Market Cap:
|
2,553(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 2:20:36 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 21.38  One year: 24.97 |
| Support: |
Support1: 12.37 Support2: 8.71 |
| Resistance: |
Resistance1: 18.3 Resistance2: 21.38 |
| Pivot: |
14.33 |
| Moving Average: |
MA(5): 16.44 MA(20): 13.79
MA(100): 8.55 MA(250): 7.71 |
| MACD: |
MACD(12,26): 1.8 Signal(9): 1.4 |
| Stochastic oscillator: |
%K(14,3): 93.5  %D(3): 93.7 |
| RSI: |
RSI(14): 77.5 |
| 52-week: |
High: 18.3 Low: 3.48 |
| Average Vol(K): |
3-Month: 5,612 (K) 10-Days: 4,579 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TGTX ] has closed below upper band by 4.3%. Bollinger Bands are 151.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
18.17 - 18.24 |
18.24 - 18.31 |
|
Low:
|
16.59 - 16.67 |
16.67 - 16.74 |
|
Close:
|
17.83 - 17.96 |
17.96 - 18.09 |
|
Company Description |
|
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York. |
Headline News |
Wed, 01 Feb 2023
BlackRock Increases Position in TG Therapeutics (TGTX) - Nasdaq
Wed, 01 Feb 2023
TG Therapeutics: Strategy After Briumvi Launch (NASDAQ:TGTX) - Seeking Alpha
Thu, 26 Jan 2023
TGTX stock gains as multiple sclerosis therapy launches (NASDAQ ... - Seeking Alpha
Tue, 24 Jan 2023
Health Care Sector Update for 01/24/2023: BIAF, JNJ, TGTX, AXLA - Nasdaq
Tue, 24 Jan 2023
Should You Sell TG Therapeutics Inc common stock (TGTX) in ... - InvestorsObserver
Mon, 23 Jan 2023
2023-01-23 | NDAQ:TGTX | Press Release | TG Therapeutics Inc. - Stockhouse
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
143 (M) |
|
% Held by Insiders
|
1.28e+008 (%) |
|
% Held by Institutions
|
8.2 (%) |
|
Shares Short
|
17,710 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.8358e+008 |
|
EPS Est Next Qtl
|
-0.45 |
|
EPS Est This Year
|
-1.85 |
|
EPS Est Next Year
|
-1.64 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-4 |
|
Return on Assets (ttm)
|
78.2 |
|
Return on Equity (ttm)
|
-48.5 |
|
Qtrly Rev. Growth
|
6.96e+006 |
|
Gross Profit (p.s.)
|
-28 |
|
Sales Per Share
|
-51.21 |
|
EBITDA (p.s.)
|
2.68182e+006 |
|
Qtrly Earnings Growth
|
-2.5 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-272 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.35 |
|
Price to Cash Flow
|
9.78 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.944e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
